BioTelemetry, Inc. Reports Third Quarter 2019 Financial Results

Exceeds Expectations
Delivers Double Digit Revenue Growth

MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the third quarter ended September 30, 2019.

Quarter Highlights  

President and CEO Commentary

Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “The third quarter was another excellent quarter for BioTelemetry, highlighted by 11% revenue growth and an adjusted EBITDA margin of 28%.  These results exceeded our expectations and marked the 29th consecutive quarter of year-over-year growth.  Demand remained strong for our Healthcare services, driven primarily by our extended Holter and MCT, which accelerated to 11% growth in the third quarter.  We also benefitted from our 2019 acquisitions, Geneva and ADEA Medical, as well as continued growth in our Research and digital population health businesses.  Our adjusted EBITDA margin also exceeded our expectations as a result of our continued focus on operational efficiencies.

“Our momentum was strengthening as we entered the fourth quarter.  However, approximately two weeks ago, we detected suspicious activity on our information technology network. As part of our comprehensive response plan, we immediately took certain systems offline to contain the activity and engaged an outside forensics team to conduct an independent investigation. Substantially all systems have resumed, and our technical team continues to work closely with third-party consultants to further address this matter. There has been no evidence of any unauthorized transfer or misuse of customer or employee data.  As always, our primary focus remains our customers and patients. 

“This incident did temporarily disrupt our services, which we expect will impact our fourth quarter results. Given the information we currently have, we now expect our full year 2019 revenue to be in the range of $435 to $440 million. 

“As we close out 2019, we will continue to execute on our proven growth strategy.  Given the strong fundamentals of our core business, coupled with our acquisitions, which have more than doubled our addressable market, we expect 2020 to be another outstanding year with double digit organic growth.”

Third Quarter Financial Results

Revenue for the third quarter 2019 was $111.3 million compared to $100.0 million for the third quarter 2018, an increase of $11.3 million, or 11.3%.

Gross profit for the third quarter 2019 was $69.3 million, or 62.3% of revenue, compared to $62.7 million, or 62.7% of revenue, for the third quarter 2018.

On a GAAP basis, net income attributable to BioTelemetry, Inc. for the third quarter 2019 was $8.3 million, or $0.23 per diluted share, compared to net income attributable to BioTelemetry, Inc. of $16.0 million, or $0.45 per diluted share, for the third quarter 2018.  The decline in net income attributable to BioTelemetry, Inc. is primarily due to a $4.7 million increase in income tax expense, with a prior year tax benefit from discrete items, as well as the ongoing investments in our salesforce and technology.  While the Company’s expected annual effective tax rate is approximately 20%, as a result of the utilization of net operating loss carryforwards, the Company expects to use approximately $1-2 million of cash for taxes in 2019.  

On an adjusted basis1, net income attributable to BioTelemetry, Inc. for the third quarter 2019 was $18.8 million, or $0.52 per diluted share.  This compares to adjusted net income attributable to BioTelemetry, Inc. of $19.2 million, or $0.53 per diluted share, for the third quarter 2018.  The impact of the ongoing investments in our salesforce and technology is being offset by the revenue growth.  The details regarding adjusted net income are included in the reconciliation tables included in this release.

1 The Company believes that providing non-GAAP financial measures offers a meaningful representation of our performance, as we exclude expenses that are not necessary to support our ongoing business.  We also make adjustments to facilitate year over year comparisons.  Please refer to our “Reconciliation of GAAP to Non-GAAP Financial Measures” in this release for additional information.

Conference Call

BioTelemetry, Inc. will host an earnings conference call on Tuesday, November 5, 2019, at 5:00 PM Eastern Time.  The call will be webcast on the investor information page of our website, www.gobio/investors/events.  The call will be archived on our website for two weeks.

About BioTelemetry

BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers.  More information can be found at www.gobio.

Cautionary Statement Regarding Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in our future.  These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning.  Examples of forward-looking statements include statements we make regarding the successful execution of our operating plan, Geneva Healthcare’s and ADEA Medical’s growth and the success of the combined entity, our ability to increase demand for our products and services, to grow our market share, to expand in the European market, our expectations regarding revenue trends in our segments, and our growth expectations for 2020.  Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations.  These factors include, among other things: our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business; our ability to educate physicians and continue to obtain prescriptions for our products and services; changes to insurance coverage and reimbursement levels by Medicare and commercial payors for our products and services; our ability to attract and retain talented executive management and sales personnel; the commercialization of new competitive products; the outcome of our pending and ongoing incident investigation, including our discovery of additional information relating to the incident and our customers’ and other stakeholders’ reactions to that additional information; costs related the incident investigation and resulting liabilities; our ability to obtain and maintain required regulatory approvals for our products, services and manufacturing facilities; changes in governmental regulations and legislation; our ability to obtain and maintain adequate protection of our intellectual property; acceptance of our new products and services; adverse regulatory action; interruptions or delays in the telecommunications systems that we use; our ability to successfully resolve outstanding legal proceedings; and the other factors that are described in “Part I; Item 1A.  Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2018, as well as the factors that are described in “Part II; Item 1A.  Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.

We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.

:       
BioTelemetry, Inc.
Heather C. Getz
Investor Relations

investorrelations

 BioTelemetry, Inc.Consolidated Statements of Operations(in thousands, except per share data)(unaudited)           Three Months Ended
September 30,
 Nine Months Ended
September 30,
     2019 2018 2019 2018Revenues $111,291  $100,013  $327,073  $295,869 Cost of revenues  41,952   37,276   122,716   109,329 Gross profit  69,339   62,737   204,357   186,540 Gross profit %  62.3%  62.7%  62.5%  63.0%         Operating expenses:        General and administrative  29,651   26,325   87,845   81,785 Sales and marketing  12,572   10,120   37,807   32,535 Bad debt expense  5,858   5,157   16,385   16,911 Research and development  3,661   2,429   10,526   8,451 Other charges  2,598   1,330   7,902   11,623 Total operating expenses  54,340   45,361   160,465   151,305          Income from operations  14,999   17,376   43,892   35,235          Other expense:        Interest expense  (2,338)  (2,408)  (7,358)  (6,982)Loss on equity method investment  (65)  (54)  (251)  (238)Other non-operating (expense)/income, net (845)  (194)  (1,813)  543 Total other expense  (3,248)  (2,656)  (9,422)  (6,677)         Income before income taxes   11,751   14,720   34,470   28,558 (Provision for)/benefit from income taxes  (3,468)  1,281   (6,202)  2,923 Net income  8,283   16,001   28,268   31,481          Net loss attributable to noncontrolling interests  –   –   –   (946)         Net income attributable to BioTelemetry, Inc. $8,283  $16,001  $28,268  $32,427                   Net income per share attributable to BioTelemetry, Inc.:          Basic $0.24  $0.48  $0.83  $1.00   Diluted $0.23  $0.45  $0.78  $0.91          Weighted average number of common shares outstanding:          Basic  33,908   33,003   33,885   32,488   Diluted  36,268   35,918   36,445   35,566          

 

BioTelemetry, Inc.Consolidated Balance Sheet       (unaudited)    September 30, December 31,  2019 2018ASSETS    Current assets:    Cash and cash equivalents $61,573 $80,889Healthcare accounts receivable, net  56,832  37,754Other accounts receivable, net  15,637  14,874Inventory  6,389  7,323Prepaid expenses and other current assets  9,712  5,820Total current assets  150,143  146,660     Property and equipment, net  55,608  48,377Intangible assets, net  133,593  129,653Goodwill  304,101  238,814Deferred tax asset  12,828  19,975Other assets  19,891  3,322Total assets $ 676,164 $ 586,801     LIABILITIES AND EQUITY    Current liabilities:    Accounts payable $19,287 $18,157Accrued liabilities  28,487  24,689Current portion of finance lease obligations  490  1,652Current portion of long-term debt  12,813  5,125Total current liabilities  61,077  49,623     Long-term portion of finance lease obligations 348  117Long-term debt  182,825  193,424Other long-term liabilities  71,007  33,152Total liabilities  315,257  276,316     Total equity  360,907  310,485     Total liabilities and equity $ 676,164 $ 586,801     

 Reconciliation of GAAP to Non-GAAP Financial Measures

              Three Months Ended (unaudited) September 30, 2019 (in thousands, except per share data) Income from operations Income before income taxes Net income
attributable to
BioTelemetry, Inc.
 Net income per
diluted share
attributable to
BioTelemetry Inc.
 GAAP $ 14,999 $ 11,751 $ 8,283  $ 0.23 Non-GAAP Adjustments:          Other charges (a)  2,598  2,598  2,598     Acquisition amortization (b)  3,668  3,668  3,668     Other expense (c)  – 677  677     Interest expense on contingent consideration (d)  – 110  110     Income tax effect of adjustments (e)  – –  (1,436)    Impact of NOL utilization (f)  – –  4,903    Non-GAAP Adjusted $ 21,265 $ 18,804 $ 18,803  $ 0.52                                     Three Months Ended (unaudited) September 30, 2018 (in thousands, except per share data) Income from Operations Income before Income Taxes Net income
attributable to
BioTelemetry, Inc.
 Net income per
diluted share
attributable to
BioTelemetry Inc.
 GAAP $ 17,376 $ 14,720 $ 16,001  $ 0.45 Non-GAAP Adjustments:          Other charges (a)  1,330  1,330  1,330     LifeWatch amortization (b)  3,267  3,267  3,267     Income tax effect of adjustments (e)  –  –  (103)    (Benefit) of discrete items / NOL utilization (f)  –  –  (1,338)   Non-GAAP Adjusted $ 21,973 $ 19,317 $ 19,157  $ 0.53            

  1. In the third quarter 2019, other charges of $2.6 million were primarily due to $2.1 million of patent litigation and other legal costs and $0.5 million of integration expense related to our acquisitions.  In the third quarter 2018, other charges of $1.3 million were due primarily to $0.7 million for the continued integration and restructuring activities related to the LifeWatch acquisition and $0.3 million for patent litigation. 
     
  2. In the third quarter 2019 and the third quarter 2018, we recognized $3.7 million and $3.3 million of expense, respectively, related to the amortization of intangibles as a result of our acquisitions.  We have excluded this amortization of intangibles from adjusted net income due to the non-operational nature of the expense.  This amortization was recorded as a component of general and administrative expense.
     
  3. In the third quarter 2019, we had an unrealized foreign exchange loss of $0.7 million
     
  4. In the third quarter 2019, we incurred $0.1 million of interest expense related to a portion of the Geneva Healthcare deferred purchase consideration.
     
  5. Represents the tax effect of the non-GAAP adjustments at the Company’s annual effective tax rate.
     
  6. After giving effect to taxes at the estimated annual effective tax rate on the adjustments, the utilization of net operating loss carryforwards had a $4.9 million positive impact on the third quarter 2019. For the third quarter 2018, we are excluding a benefit of $1.3 million from discrete items.

              Nine Months Ended (unaudited) September 30, 2019 (in thousands, except per share data) Income from operations Income before
income taxes
 Net income
attributable to
BioTelemetry, Inc.
 Net income per
diluted share
attributable to
BioTelemetry Inc.
 GAAP $ 43,892 $ 34,470  $ 28,268  $ 0.78 Non-GAAP Adjustments:          Other charges (a)  7,902  7,902   7,902     Acquisition amortization (b)  10,742  10,742   10,742     Other expense adjustments (c)  –  1,479   1,479     Interest expense on contingent consideration (d)  –  240   240     Income tax effect of adjustments (e)  –  –   (4,146)    Impact of NOL utilization (f)  –  –   8,942    Non-GAAP Adjusted $ 62,536 $ 54,833  $ 53,427  $ 1.47                          Nine Months Ended (unaudited) September 30, 2018 (in thousands, except per share data) Income from Operations Income (loss)
before
Income Taxes
 Net income
attributable to
BioTelemetry, Inc.
 Net income per
diluted share
attributable to
BioTelemetry Inc.
 GAAP $ 35,235 $ 28,558  $ 32,427  $ 0.91 Non-GAAP Adjustments:          Other charges (a)  11,623  11,623   11,623     LifeWatch amortization (b)  9,852  9,852   9,852     Other expense adjustments (c)  –  (748)  (748)    Income tax effect of adjustments (e)  –  –   (464)    (Benefit) of discrete items / NOL utilization (f)  –  –   (3,341)   Non-GAAP Adjusted $ 56,710 $ 49,285  $ 49,349  $ 1.39            

  1. For the nine months ended September 30, 2019, other charges of $7.9 million were due primarily to $5.8 million of patent litigation and other legal costs, $1.6 million of costs related to our acquisitions and $0.5 million for other non-recurring activities.  For the nine months ended September 30, 2018, other charges of $11.6 million consisted of $7.9 million for the continued integration and restructuring activities related to the LifeWatch acquisition, a $1.8 million reserve for a note receivable with a bankrupt customer, $1.5 million for patent litigation, $0.8 million of other expense including legal, professional fees and depreciation, partially offset by a $0.7 million reduction in contingent consideration related to a 2016 acquisition.
     
  2. For the nine months ended September 30, 2019 and September 30, 2018, we recognized $10.7 million and $9.9 million of expense, respectively, related to the amortization of intangibles as a result of our acquisitions.  We have excluded this amortization of intangibles from adjusted net income due to the non-operational nature of the expense.  This amortization was recorded as a component of general and administrative expense.
     
  3. For the nine months ended September 30, 2019, we had an unrealized foreign exchange loss of $2.2 million partially offset by a $0.7 million gain associated with the termination of a former LifeWatch foreign pension plan.  For the nine months ended September 30, 2018, we incurred $0.3 million of interest related to a ruling on an arbitration demand filed against LifeWatch prior to the acquisition.  This was offset by an unrealized foreign exchange gain of $1.0 million. These expenses were recorded as a component of other expense. 
     
  4. For the nine months ended September 30, 2019, we incurred $0.2 million of interest expense related to a portion of the Geneva Healthcare deferred purchase consideration.
     
  5. Represents the tax effect of the non-GAAP adjustments at the Company’s annual effective tax rate.
     
  6. After giving effect to taxes at the estimated annual effective tax rate on the adjustments, the utilization of net operating loss carryforwards had a $8.9 million positive impact on the nine months ended September 30, 2019. For the nine months ended September 30, 2018, the Company is excluding a $3.3 million benefit from discrete items.

 (unaudited) Three Months Ended
September 30,
 Nine Months Ended
September 30,
(in thousands) 2019 2018 2019 2018Net income attributable to BioTelemetry – GAAP $ 8,283  $ 16,001  $ 28,268  $ 32,427 Net loss attributable to noncontrolling interest  –    –    –    (946)Provision for/(benefit from) income taxes  3,468   (1,281)  6,202   (2,923)Total other expense  3,248   2,656   9,422   6,677 Other charges  2,598   1,330   7,902   11,623 Depreciation and amortization expense (a)  10,295   10,063   30,508   29,757 Stock compensation expense  3,636   1,355   9,662   6,278 Adjusted EBITDA  $ 31,528  $ 30,124  $ 91,964  $ 82,893 Adjusted EBITDA margin  28.3%  30.1%  28.1%  28.0%         

  1. For the nine months ended September 30, 2018, depreciation and amortization expense excludes $0.5 million of expense related to the write-off of assets as a result of the dissolution of entities acquired as part of the LifeWatch acquisition. This expense is included in Other charges.
                 

 Summary Cash Flow Data         (unaudited) Three Months Ended
September 30,
 Nine Months Ended
September 30,
   (in thousands) 2019 2018 2019 2018Cash provided by operating activities $16,472  $28,151  $52,602  $44,287 Capital expenditures  (7,594)  (7,561)  (23,686)  (17,498)Free cash flow $ 8,878  $ 20,590  $ 28,916  $ 26,789          

Use of Non-GAAP Financial Measures

In addition to the results prepared in accordance with generally accepted accounting principles in the United States, (“GAAP”), this press release also includes certain financial measures which have been adjusted and are not in accordance with generally accepted accounting principles (“Non-GAAP financial measures”).  These Non-GAAP financial measures include adjusted income from operations, adjusted income before income taxes, adjusted net income attributable to BioTelemetry, Inc., adjusted net income per diluted share attributable to BioTelemetry, Inc., adjusted EBITDA and free cash flow.  In accordance with Regulation G of the Securities and Exchange Commission, we have provided a reconciliation of these Non-GAAP financial measures with the most directly comparable financial measure calculated in accordance with GAAP.

These Non-GAAP financial measures are not intended to replace GAAP financial measures.  They are presented as supplemental measures of our performance in an effort to provide our stakeholders better visibility into our ongoing operating results and to allow for comparability to prior periods as well as to other companies’ results.  Management uses these Non-GAAP  financial measures to assess the financial health of our ongoing operating performance.  Management encourages our stakeholders to consider all of our financial measures and to not rely on any single financial measure to evaluate our performance.

Adjusted net income attributable to BioTelemetry, Inc. for the third quarter 2019 excludes other charges of $2.6 million, $3.7 million of amortization expense related to our acquisitions, $0.7 million of unrealized foreign currency loss, $0.1 million of interest expense related to a portion of the Geneva Healthcare contingent consideration, the tax effect of these adjustments as well as the impact from the utilization of our net operating loss carryforwards.  Adjusted net income attributable to BioTelemetry, Inc. for the third quarter 2018 excludes other charges of $1.3 million, $3.3 million of amortization expense related to LifeWatch intangibles, the tax effect of these adjustments as well as the impact from the utilization of our net operating loss carryforwards. By excluding expenses that are considered unnecessary to support the ongoing business, are nonrecurring in nature or which limit year over year comparability, we believe these Non-GAAP financial measures offer a meaningful representation of our ongoing operating performance.  Included in these excluded items are transaction related expenses, primarily legal and professional fees, integration related expenses, primarily severance, legal fees related to patent litigation, amortization of intangibles from the LifeWatch and Geneva acquisitions, costs related to restructuring programs aimed at streamlining operations and reducing future expense as well as other one-time items.  These excluded charges are not part of the ongoing operations, and therefore, not reflective of our core operations.  We view patent litigation as an extreme measure not typically required in our industry to protect a company’s intellectual property and which has not been common practice for us.  We commenced patent litigation proceedings after we uncovered specific evidence of four distinct cases of misappropriation and infringement.  We can choose to resolve the outstanding matters and terminate the expense at any time.  We also included the income tax effect of these adjustments.
       
In addition to adjusted income from operations, adjusted net income attributable to BioTelemetry, Inc., adjusted net income per diluted share attributable to BioTelemetry, Inc. and free cash flow, we also present adjusted EBITDA.  This Non-GAAP financial measure excludes loss from noncontrolling interest, income taxes, total other expense, other charges, depreciation and amortization and stock compensation expense.  EBITDA is a widely accepted financial measure which we believe our stakeholders use to compare our ongoing financial performance to that of other companies.  Adjusting our EBITDA for other charges and other one-time items is a meaningful financial measure as we believe it is an indication of our ongoing operations.  In addition, we also add back stock-based compensation expense because it is non-cash in nature.  Other companies in our industry may calculate adjusted EBITDA in a different manner.